When progression-free survival fails to inform: the need for event-level reporting in oligometastatic radiotherapy trials
Authors:
- Cole FriedesCFCole Friedes
- David PalmaDPDavid Palma
- Nina N. SanfordNSNina N. Sanford
- 2 September 2026
- journal article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 224
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Real-World Endpoints in Stereotactic Body Radiation Therapy Trials for Oligoprogression: Beyond Progression-Free Survival and Overall SurvivalInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2025
- LBA72 NorthStar: A phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC)Annals of Oncology, 2025
- Rethinking clinical trial endpoints for evaluating serially delivered ‘strategic radiotherapy’ in oligometastatic or oligoprogressive metastatic diseaseCancer Letters, 2025
- Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate CancerJAMA Oncology, 2023
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerJAMA Oncology, 2020
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung CancerJAMA Oncology, 2017
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Composite Outcomes in Randomized TrialsJAMA, 2003